CDK6 and neoplasm: Palbociclib is an orally active and highly selective inhibitor of CDK4 and CDK6 kinases, which could block the phosphorylation of retinoblastoma (Rb), subsequently preventing progression of the cell cycle from G1 into the S phase in the Rb-positive cells of various tumor types5–7.